Cellectar Biosciences (CLRB) to Release Earnings on Wednesday

Cellectar Biosciences (NASDAQ:CLRB) is projected to release its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Cellectar Biosciences to post earnings of ($1.20) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:30 AM ET.

Cellectar Biosciences Stock Down 7.7%

Cellectar Biosciences stock opened at $3.24 on Monday. The company’s 50-day moving average price is $3.26 and its two-hundred day moving average price is $3.90. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 0.04. The stock has a market cap of $13.74 million, a P/E ratio of -0.35 and a beta of 0.31. Cellectar Biosciences has a twelve month low of $2.45 and a twelve month high of $20.60.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CLRB. XTX Topco Ltd bought a new stake in shares of Cellectar Biosciences in the fourth quarter valued at approximately $36,000. Bank of America Corp DE grew its stake in Cellectar Biosciences by 25.3% during the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 41,704 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Cellectar Biosciences during the third quarter worth about $73,000. Geode Capital Management LLC increased its holdings in Cellectar Biosciences by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 3,744 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Cellectar Biosciences in the 3rd quarter valued at approximately $104,000. 16.41% of the stock is owned by institutional investors.

About Cellectar Biosciences

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.